CAM-话题@MedSci

#CAM#

107篇内容 | 2864人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1675371, encodeId=35f816e5371eb, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, objectType=article, longId=208823, objectId=6828208823c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6828208823c0, replyNumber=0, likeNumber=69, createdTime=2021-10-13, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6828208823c0, moduleTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6828208823c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675375, encodeId=226a16e537539, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=124, createdTime=2021-09-27, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675373, encodeId=b40716e53739b, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况, objectType=article, longId=211560, objectId=b35921156090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b35921156090, replyNumber=0, likeNumber=64, createdTime=2021-10-19, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b35921156090, moduleTitle=Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b35921156090)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675369, encodeId=e4ec16e5369f7, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=NEJM：Omecamtiv mecarbil用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=205729, objectId=ef5c205e29f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef5c205e29f7, replyNumber=0, likeNumber=118, createdTime=2021-07-28, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef5c205e29f7, moduleTitle=NEJM：Omecamtiv mecarbil用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef5c205e29f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675365, encodeId=dc9d16e536503, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, objectType=article, longId=202096, objectId=825120209604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825120209604, replyNumber=0, likeNumber=60, createdTime=2020-11-16, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825120209604, moduleTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825120209604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675374, encodeId=8ab316e537413, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效, objectType=article, longId=212462, objectId=1f99212462e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f99212462e3, replyNumber=0, likeNumber=70, createdTime=2021-09-11, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f99212462e3, moduleTitle=Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f99212462e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675363, encodeId=bcd516e536314, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：抗ICAM1抗体-药物偶联物用于多发性骨髓瘤的潜在活性, objectType=article, longId=200931, objectId=c7f6200931f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7f6200931f1, replyNumber=0, likeNumber=73, createdTime=2020-10-18, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7f6200931f1, moduleTitle=Clin Cancer Res：抗ICAM1抗体-药物偶联物用于多发性骨髓瘤的潜在活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7f6200931f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten, objectType=article, longId=203521, objectId=7249203521e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7249203521e8, replyNumber=0, likeNumber=105, createdTime=2021-01-07, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7249203521e8, moduleTitle=131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7249203521e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675372, encodeId=729116e5372c9, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, objectType=article, longId=208916, objectId=dc73208916ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc73208916ac, replyNumber=0, likeNumber=81, createdTime=2021-12-20, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73208916ac, moduleTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73208916ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675360, encodeId=380416e5360fd, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！, objectType=article, longId=200122, objectId=01d820012261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01d820012261, replyNumber=0, likeNumber=84, createdTime=2021-04-20, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01d820012261, moduleTitle=Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01d820012261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675368, encodeId=b44816e5368c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , objectType=article, longId=204057, objectId=4ed120405e9f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ed120405e9f, replyNumber=0, likeNumber=66, createdTime=2021-04-26, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ed120405e9f, moduleTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ed120405e9f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675359, encodeId=f79616e535927, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=我国4.2%心梗患者有家族性高胆固醇血症！CAMI研究新分析, objectType=article, longId=199246, objectId=570b199246ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570b199246ae, replyNumber=0, likeNumber=64, createdTime=2020-12-15, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570b199246ae, moduleTitle=我国4.2%心梗患者有家族性高胆固醇血症！CAMI研究新分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=570b199246ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675361, encodeId=9dab16e5361b1, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：PD1阻断可增强ICAM1靶向CAR T细胞对晚期甲状腺癌的治疗效果, objectType=article, longId=200373, objectId=1d9e2003e395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9e2003e395, replyNumber=0, likeNumber=63, createdTime=2020-12-12, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9e2003e395, moduleTitle=Clin Cancer Res：PD1阻断可增强ICAM1靶向CAR T细胞对晚期甲状腺癌的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9e2003e395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675370, encodeId=f20316e5370dc, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, objectType=article, longId=206165, objectId=19d8206165d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d8206165d9, replyNumber=0, likeNumber=89, createdTime=2021-11-07, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d8206165d9, moduleTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d8206165d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675358, encodeId=b2cf16e5358db, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Abcam 成功收购 MarkerGene Technologies, objectType=article, longId=191088, objectId=f11719108868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f11719108868, replyNumber=0, likeNumber=63, createdTime=2021-01-02, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f11719108868, moduleTitle=Abcam 成功收购 MarkerGene Technologies, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f11719108868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675357, encodeId=a0b016e5357eb, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Abcam荣获2020年CiteAb更佳抗体供应商奖, objectType=article, longId=190736, objectId=c87e190e365d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c87e190e365d, replyNumber=0, likeNumber=63, createdTime=2021-02-27, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c87e190e365d, moduleTitle=Abcam荣获2020年CiteAb更佳抗体供应商奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c87e190e365d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675364, encodeId=a97616e536426, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Clin Cancer Res：阻断PD1可增强ICAM1靶向CAR T细胞治疗晚期甲状腺癌的疗效, objectType=article, longId=201674, objectId=cc9f2016e48a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc9f2016e48a, replyNumber=0, likeNumber=80, createdTime=2021-08-30, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc9f2016e48a, moduleTitle=Clin Cancer Res：阻断PD1可增强ICAM1靶向CAR T细胞治疗晚期甲状腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc9f2016e48a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Blood：血小板反应蛋白-1通过调节血小板的cAMP信号促进止血, objectType=article, longId=200715, objectId=4f0a200e151a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f0a200e151a, replyNumber=0, likeNumber=74, createdTime=2020-12-27, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f0a200e151a, moduleTitle=Blood：血小板反应蛋白-1通过调节血小板的cAMP信号促进止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f0a200e151a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675366, encodeId=d51f16e536656, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移, objectType=article, longId=202254, objectId=d2c520225459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2c520225459, replyNumber=0, likeNumber=54, createdTime=2021-02-24, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2c520225459, moduleTitle=Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2c520225459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675352, encodeId=1a6a16e535213, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, objectTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, objectType=article, longId=185991, objectId=6b1e18599136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1e18599136, replyNumber=0, likeNumber=62, createdTime=2020-09-12, rootId=0, userName=whmdzju, userId=16ac27217804, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1e18599136, moduleTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1e18599136)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAM

2020-05-29

whmdzju (审核中...)

前往app查看评论内容

#CAM#

FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请

2021-10-13

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-09-27

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况

2021-10-19

whmdzju (审核中...)

前往app查看评论内容

#CAM#

NEJM：Omecamtiv mecarbil用于治疗射血分数降低的心力衰竭患者

2021-07-28

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性

2020-11-16

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效

2021-09-11

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：抗ICAM1抗体-药物偶联物用于多发性骨髓瘤的潜在活性

2020-10-18

whmdzju (审核中...)

前往app查看评论内容

#CAM#

131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten

2021-01-07

whmdzju (审核中...)

前往app查看评论内容

#CAM#

J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果

2021-12-20

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！

2021-04-20

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果

2021-04-26

whmdzju (审核中...)

前往app查看评论内容

#CAM#

我国4.2%心梗患者有家族性高胆固醇血症！CAMI研究新分析

2020-12-15

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：PD1阻断可增强ICAM1靶向CAR T细胞对晚期甲状腺癌的治疗效果

2020-12-12

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点

2021-11-07

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Abcam 成功收购 MarkerGene Technologies

2021-01-02

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Abcam荣获2020年CiteAb更佳抗体供应商奖

2021-02-27

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Clin Cancer Res：阻断PD1可增强ICAM1靶向CAR T细胞治疗晚期甲状腺癌的疗效

2021-08-30

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Blood：血小板反应蛋白-1通过调节血小板的cAMP信号促进止血

2020-12-27

whmdzju (审核中...)

前往app查看评论内容

#CAM#

Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移

2021-02-24

whmdzju (审核中...)

前往app查看评论内容

#CAM#

美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症

2020-09-12

科室
- - 订阅+
  - 更多科室
工具
服务